Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report

Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report

Brand Name Pharmaceutical Manufacturing in the US

Over the past five years, the Brand Name Pharmaceutical Manufacturing industry has experienced several new drug launches, with over 28 novel drugs approved in 2022 (latest data available). Given increasing price scrutiny, competition from generics, intensifying market competition among brand-name producers and rising research and development expenses, many manufacturers have shifted their strategic focus to more lucrative therapy areas, such as rare diseases and oncology. As a result, many companies pivoted their pipelines to rare diseases, in which low prescription volumes can be offset by high per-unit costs and benefit from orphan drug exclusivity, which grants longer patent exclusivity in the United States and the European Union. Overall, industry revenue has increased at a CAGR of 3.2% over the past five years, reaching $239.8 billion in 2022. This includes an 0.4% increase in 2023 alone.

Pharmaceutical manufacturers develop prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Brand-name drugs and medication have patent protection. This industry does not include nutritional supplement or cosmetic product manufacturers.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.